Comparative Pharmacology
Head-to-head clinical analysis: DISOPYRAMIDE PHOSPHATE versus QUALAQUIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOPYRAMIDE PHOSPHATE versus QUALAQUIN.
DISOPYRAMIDE PHOSPHATE vs QUALAQUIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; inhibits cardiac sodium channels, prolongs action potential duration, increases effective refractory period, and reduces myocardial excitability and conduction velocity.
Quinine is a cinchona alkaloid that acts as a blood schizonticide against Plasmodium species. It inhibits heme polymerase in the parasite, leading to accumulation of toxic heme and parasite death. It also has weak gametocytocidal activity against P. vivax and P. malariae.
100-200 mg orally every 6 hours; immediate-release: 100-200 mg every 6 hours; extended-release: 200-300 mg every 12 hours.
325-650 mg orally every 6 hours as needed for pain; maximum 2.6 g/day.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged to 15-25 hours in renal impairment (creatinine clearance <40 mL/min), requiring dose adjustment.
Terminal elimination half-life approximately 8 hours in healthy adults; prolonged in hepatic impairment (up to 12-18 hours) and severe malaria (up to 14-20 hours).
Renal excretion of unchanged drug accounts for 40-60% of elimination; hepatic metabolism (N-dealkylation) accounts for 20-30%; approximately 10-15% excreted in feces via biliary elimination.
Renal (approximately 20% unchanged; remainder as metabolites); biliary/fecal (minor).
Category D/X
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)